JP2017525684A - Ｎ−メチル−ｄ−アスパラギン酸受容体モジュレーターならびにその製造方法及び使用方法 - Google Patents

Ｎ−メチル−ｄ−アスパラギン酸受容体モジュレーターならびにその製造方法及び使用方法 Download PDF

Info

Publication number
JP2017525684A
JP2017525684A JP2017503919A JP2017503919A JP2017525684A JP 2017525684 A JP2017525684 A JP 2017525684A JP 2017503919 A JP2017503919 A JP 2017503919A JP 2017503919 A JP2017503919 A JP 2017503919A JP 2017525684 A JP2017525684 A JP 2017525684A
Authority
JP
Japan
Prior art keywords
alkyl
group
independently selected
ring atoms
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017503919A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525684A5 (enExample
Inventor
エム アミン カン
エム アミン カン
Original Assignee
ノーレックス インコーポレイテッド
ノーレックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノーレックス インコーポレイテッド, ノーレックス インコーポレイテッド filed Critical ノーレックス インコーポレイテッド
Publication of JP2017525684A publication Critical patent/JP2017525684A/ja
Publication of JP2017525684A5 publication Critical patent/JP2017525684A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
JP2017503919A 2014-07-24 2015-07-24 Ｎ−メチル−ｄ−アスパラギン酸受容体モジュレーターならびにその製造方法及び使用方法 Pending JP2017525684A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462028512P 2014-07-24 2014-07-24
US62/028,512 2014-07-24
US201562129388P 2015-03-06 2015-03-06
US62/129,388 2015-03-06
PCT/US2015/042070 WO2016014982A1 (en) 2014-07-24 2015-07-24 N-methyl-d-aspartate receptor modulators and methods of making and using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020114862A Division JP2020176124A (ja) 2014-07-24 2020-07-02 Ｎ−メチル−ｄ−アスパラギン酸受容体モジュレーターならびにその製造方法及び使用方法

Publications (2)

Publication Number Publication Date
JP2017525684A true JP2017525684A (ja) 2017-09-07
JP2017525684A5 JP2017525684A5 (enExample) 2018-10-04

Family

ID=55163858

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017503919A Pending JP2017525684A (ja) 2014-07-24 2015-07-24 Ｎ−メチル−ｄ−アスパラギン酸受容体モジュレーターならびにその製造方法及び使用方法
JP2020114862A Pending JP2020176124A (ja) 2014-07-24 2020-07-02 Ｎ−メチル−ｄ−アスパラギン酸受容体モジュレーターならびにその製造方法及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020114862A Pending JP2020176124A (ja) 2014-07-24 2020-07-02 Ｎ−メチル−ｄ−アスパラギン酸受容体モジュレーターならびにその製造方法及び使用方法

Country Status (6)

Country Link
US (2) US9994614B2 (enExample)
EP (2) EP3916003A1 (enExample)
JP (2) JP2017525684A (enExample)
AU (2) AU2015292324A1 (enExample)
CA (1) CA2955196A1 (enExample)
WO (1) WO2016014982A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210198315A1 (en) * 2016-02-01 2021-07-01 Naurex, INC Process for synthesis of peptide compounds
CN107200725B (zh) * 2016-03-18 2021-06-29 江苏恒瑞医药股份有限公司 稠杂环类衍生物、其制备方法及其在医药上的应用
CN108148113A (zh) * 2016-12-06 2018-06-12 深圳先进技术研究院 一种nmda受体调控剂四肽衍生物的固相合成方法
CN107474107B (zh) * 2017-05-18 2023-01-17 江苏恩华药业股份有限公司 Glyx-13的制备方法及用于制备glyx-13的化合物
US20200199173A1 (en) * 2017-07-28 2020-06-25 Naurex, Inc. Process and intermediates for synthesis of peptide compounds

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59104350A (ja) * 1982-11-10 1984-06-16 フアルムイタリア・カルロ・エルバ・ソシエタ・ペル・アチオ−ニ 生物学的に活性なペプチド及びその製造方法，該ペプチドを含む動物用成長促進剤
JPS62286997A (ja) * 1986-05-31 1987-12-12 ビクトル　ブランデル 薬理的に活性のあるペプチッド
WO1998042732A1 (en) * 1997-03-25 1998-10-01 The Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
JP2000501746A (ja) * 1996-05-17 2000-02-15 ニューロセラピューティクス エル．ピー． 神経刺激性ペプチド
WO2007112492A1 (en) * 2006-03-31 2007-10-11 The University Of Queensland Compounds and methods for the treatment of pain
WO2011003064A2 (en) * 2009-07-02 2011-01-06 Naurex, Inc. Methods of treating neuropathic pain
JP2013504619A (ja) * 2009-09-15 2013-02-07 サイトジェル ファーマ リミテッド ライアビリティ カンパニー 有利なμ−オピエート受容体ペプチド化合物
JP2013519683A (ja) * 2010-02-11 2013-05-30 ノースウエスタン ユニバーシティ Ｎｍｄａ受容体モジュレータを安定化させる二次構造及びその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007088099A2 (en) * 2006-01-13 2007-08-09 Oncoreg Ab Compounds for the treatment of ischemia and neurodegeneration
BRPI0918868B8 (pt) * 2008-09-18 2021-05-25 Naurex Inc compostos moduladores do receptor de nmda e composições compreendendo os mesmos
WO2010065709A2 (en) * 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
KR101692275B1 (ko) * 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59104350A (ja) * 1982-11-10 1984-06-16 フアルムイタリア・カルロ・エルバ・ソシエタ・ペル・アチオ−ニ 生物学的に活性なペプチド及びその製造方法，該ペプチドを含む動物用成長促進剤
JPS62286997A (ja) * 1986-05-31 1987-12-12 ビクトル　ブランデル 薬理的に活性のあるペプチッド
JP2000501746A (ja) * 1996-05-17 2000-02-15 ニューロセラピューティクス エル．ピー． 神経刺激性ペプチド
WO1998042732A1 (en) * 1997-03-25 1998-10-01 The Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
WO2007112492A1 (en) * 2006-03-31 2007-10-11 The University Of Queensland Compounds and methods for the treatment of pain
WO2011003064A2 (en) * 2009-07-02 2011-01-06 Naurex, Inc. Methods of treating neuropathic pain
JP2013504619A (ja) * 2009-09-15 2013-02-07 サイトジェル ファーマ リミテッド ライアビリティ カンパニー 有利なμ−オピエート受容体ペプチド化合物
JP2013519683A (ja) * 2010-02-11 2013-05-30 ノースウエスタン ユニバーシティ Ｎｍｄａ受容体モジュレータを安定化させる二次構造及びその使用

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
"RN:1025951-09-0", DATABASE REGISTRY [ONLINE] RETRIEVED FROM STN, JPN6019022921, 6 June 2008 (2008-06-06), ISSN: 0004223709 *
"RN:1222522-72-6", DATABASE REGISTRY [ONLINE] RETRIEVED FROM STN, JPN6019022919, 12 May 2010 (2010-05-12), ISSN: 0004223708 *
ARKIVOC, vol. 5, JPN6019022886, 2012, pages 163 - 174, ISSN: 0004223701 *
AUSTRALIAN JOURNAL OF CHEMISTRY, vol. Vol.47(11), JPN6019022883, 1994, pages 2099 - 2108, ISSN: 0004223698 *
AUSTRALIAN JOURNAL OF CHEMISTRY, vol. Vol.52(7), JPN6019022902, 1999, pages 639 - 645, ISSN: 0004223707 *
BIOORGANIC & MEDICINAL CHEMISTRY, vol. Vol.15(3), JPN6019022890, 2007, pages 1237 - 1251, ISSN: 0004223703 *
BIOORGANIC & MEDICINAL CHEMISTRY, vol. Vol.16(8), JPN6019022888, 2008, pages 4341 - 4346, ISSN: 0004223702 *
BRITISH JOURNAL OF PHARMACOLOGY, vol. Vol.137(8), JPN6019022923, 2002, pages 1143 - 1146, ISSN: 0004223699 *
INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS, vol. Vol.12(2), JPN6019022893, 2006, pages 145 - 151, ISSN: 0004223704 *
JOURNAL OF MEDICINAL CHEMISTRY, vol. Vol.47(3), JPN6019022897, 2004, pages 735 - 743, ISSN: 0004223705 *
MEDCHEMCOMM, vol. Vol.4(7), JPN6019022880, 2013, pages 1114 - 1117, ISSN: 0004223697 *
ORGANIC & BIOMOLECULAR CHEMISTRY, vol. Vol.1(9), JPN6019022899, 2003, pages 1498 - 1502, ISSN: 0004223706 *
TETRAHEDRON LETTERS, vol. Vol.51(1), JPN6019022924, 2010, pages 2576 - 2579, ISSN: 0004223700 *

Also Published As

Publication number Publication date
EP3171941A4 (en) 2018-03-21
JP2020176124A (ja) 2020-10-29
AU2021201006A1 (en) 2021-03-11
US20180258139A1 (en) 2018-09-13
WO2016014982A1 (en) 2016-01-28
US9994614B2 (en) 2018-06-12
EP3916003A1 (en) 2021-12-01
EP3171941A1 (en) 2017-05-31
AU2015292324A8 (en) 2017-03-30
EP3171941B1 (en) 2021-03-24
AU2015292324A1 (en) 2017-02-23
CA2955196A1 (en) 2016-01-28
US20170210779A1 (en) 2017-07-27

Similar Documents

Publication Publication Date Title
AU2019204073B2 (en) NMDA receptor modulators and uses thereof
JP6564513B2 (ja) スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
AU2014212485C1 (en) Spiro-lactam NMDA receptor modulators and uses thereof
AU2014212487C1 (en) Spiro-lactam NMDA receptor modulators and uses thereof
EP2951185B1 (en) Spiro-lactam nmda receptor modulators and uses thereof
JP2020176124A (ja) Ｎ−メチル−ｄ−アスパラギン酸受容体モジュレーターならびにその製造方法及び使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180724

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180821

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190624

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190924

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200302